Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plumat Introduces New Automatic Aseptic Filling, Sealing Line
Plumat said that BFL 854 offers control over safety issues as well as a reduction in product contamination risk during the fill/seal process. Plumat claimed that the new
Plumat said that BFL 854 offers control over safety issues as well as a reduction in product contamination risk during the fill/seal process. Plumat claimed that the new
Palex had recently launched Detect-Ready MRSA assay into the Spanish market. MDI claimed that with the Detect-Ready MRSA assay, healthcare providers would benefit with enhanced accuracy, speed, flexibility
Intercell’s vaccine, which helps to prevent Japanese Encephalitis, has already been approved and launched in the USA, Europe, Canada and Australia. Ixiaro is a modern purified, inactivated vaccine
Asuragen manufactures the monitoring test, which is exclusively distributed by Life Technologies and runs on the Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument. The test monitors
PPI-461 is Presidio Pharma’s lead HCV NS5A inhibitor. The trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest
Neptune has posted a net income of $476,000 for the Q1 ended May 31, 2010, compared to a net loss of $1,407,000 for the corresponding period ended May
Prior to Novartis, Dr Brennan worked at Fidelity Biosciences and prior to that worked in business development for several early-stage biotechnology companies. Jeffrey Hatfield, CEO of Vitae Pharmaceuticals,
Earlier, Aestus has identified several products to treat certain psychiatric disorders. Now in partnership with Eisai, Aestus is expected to use those products for potential subsequent development in
Peregrine Pharma said that the current study is based on the positive Phase II NSCLC study results, which showed an ORR of 43% (21 of 49 patients) and
In the study, ISTA Pharma is expected to evaluate the safety and efficacy of three concentrations of Bepotastine Besilate, dosed twice daily, in an Environmental Exposure Chamber (EEC)